BioRestorative announces initiative to target polycystic ovarian syndrome
BioRestorative Therapies announced that it has expanded its "off-the-shelf" brown adipose derived stem cell therapeutic pipeline to target polycystic ovarian syndrome. PCOS is the most common reproductive endocrine disease, and can often lead to infertility, with up to 5 million patients in the United States. PCOS is difficult to manage and the current standard of care, including lifestyle changes and multi-line medications, may be moderately effective and unable to address long-term risks of type 2 diabetes, cardiovascular disease and psychiatric problems. The Company hopes that its novel platform technology, using brown adipose derived stem cells, will become an emerging therapy for PCOS. The mechanisms of action involve both metabolic remodeling and endocrine secretions of the transplanted brown adipocytes that target both the PCOS metabolic symptoms as well as endocrine dysregulation. Collectively existing literature and the Company's research and development supports transplanting metabolically active brown adipocytes to potentially improve or cure PCOS.